Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastases

This study evaluated the dose–response relation for zoledronic acid, a new generation high potency bisphosphonate, given as a 5‐minute infusion in patients with malignant osteolytic disease.

[1]  L. Rosen,et al.  A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  G. Mills,et al.  Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Berenson,et al.  A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease , 2001, Cancer.

[4]  B. Hillner,et al.  American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer , 2000 .

[5]  G. Hortobagyi,et al.  Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases , 2000, Cancer.

[6]  J. Stoker,et al.  The Department of Health and Human Services. , 1999, Home healthcare nurse.

[7]  Kathryn A. Lee,et al.  Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study. , 1999, Journal of pain and symptom management.

[8]  G. Hortobagyi,et al.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Hortobagyi,et al.  Markers of bone resorption in patients treated with pamidronate. , 1998, European journal of cancer.

[10]  D. Giannarelli,et al.  Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. , 1998, International journal of radiation oncology, biology, physics.

[11]  B. Barlogie,et al.  Biologic and therapeutic determinants of bone mineral density in multiple myeloma. , 1998, Leukemia & lymphoma.

[12]  O. S. Nielsen,et al.  Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  G. Hortobagyi,et al.  Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Powles,et al.  Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. , 1998, Journal of the National Cancer Institute.

[15]  R. Bell,et al.  Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Lipton.  Bisphosphonates and breast carcinoma , 1997, Cancer.

[17]  P. Burckhardt.  Ibandronate in oncology , 1997, Cancer.

[18]  L. Widler,et al.  Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. , 1997, Pharmacology & toxicology.

[19]  G. Hortobagyi,et al.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.

[20]  R. Recker,et al.  Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis , 1996 .

[21]  M. Kovacs,et al.  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.

[22]  K. Goa,et al.  Clodronate , 1994, Drugs.

[23]  K. Jaeggi,et al.  Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  C. Cleeland,et al.  Pain assessment: global use of the Brief Pain Inventory. , 1994, Annals of the Academy of Medicine, Singapore.

[25]  D. McTavish,et al.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. , 1991, Drugs.

[26]  C. Newstead,et al.  Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia. , 1990, Bone and mineral.